GI Oncology
News
FDA approves bevacizumab for second-line combinations
News
Resecting residual gastrointestinal stromal tumors improved survival
Major Finding: Time to tumor progression was 88 months in 42 patients who had surgery for residual disease and 42 months in 92 patients given...
News
Second-line docetaxel benefits seen for esophagogastric cancers
Major Finding: Docetaxel significantly increased overall survival from a median of 3.6 months to 5.2 months and reduced pain scores in patients...
News
Statins cut risk of hepatocellular carcinoma
Major Finding: Statin therapy reduced the risk of developing hepatocellular carcinoma by 37% overall; the risk reduction was stronger (48%) in...
News
Ten percent of neoplastic polyps may be incompletely resected
Major Finding: Ten percent of neoplastic polyps (5-20 mm) were not resected completely, as evidenced by neoplastic tissue in biopsies from the...
News
Poor performance seen after optical biopsy training
Major Finding: Three of 12 community gastroenterologists learned to distinguish adenomatous from hyperplastic colon polyps 5 mm in size or smaller...
News
Tivantinib Shows Modest Benefit in Relapsed Liver Cancer
Major Finding: Median time to progression, the primary end point, was 6.9 weeks for patients randomized to tivantinib, compared with 6.0 weeks for...
News
Brivanib Can't Match Sorafenib for Advanced Liver Cancer
Major Finding: Comparisons of the median overall survival between brivanib- and sorafenib-treated patients showed an overall hazard ratio of 1.07...
News
Earlier End-of-Life Talks Deter Aggressive Care of Terminal Cancer Patients
Major Finding: Chemotherapy in the last 2 weeks of life was 59% less likely, acute care in the last 30 days was 57% less likely, and ICU care in...
News
Antivirals Linked to Lower Risk of Liver Cancer Return
Major Finding: The cumulative 6-year rate of hepatocellular carcinoma recurrence was 45.6% for patients taking nucleoside analogues and 54.6% for...